3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial
David R. Holmes, Jr, MD*,*,
Paul S. Teirstein, MD ,
Lowell Satler, MD ,
Michael H. Sketch, Jr, MD ,
Jeffery J. Popma, MD||,
Laura Mauri, MD, MSc||,
Hong (Patrick) Wang, MD, MPH¶,
Patricia A. Schleckser, BS¶,
Sidney A. Cohen, MD, PhD¶ SISR Investigators
* Department of Cardiology, Mayo Clinic, Rochester, Minnesota
Scripps Memorial Hospital, La Jolla, California
Washington Hospital Center, Washington, DC
Duke University Medical Center, Durham, North Carolina
|| Brigham & Women's Hospital, Boston, Massachusetts
¶ Cordis Corporation, Warren, New Jersey.
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Curves and Survival Table for the End Point of TLR to 1,080 Days
In patients treated with the Cypher stent (Cordis), freedom from target lesion revascularization (TLR) remains significantly better than vascular brachytherapy throughout the 3-year follow-up period (log-rank p = 0.018).
|
|
View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Kaplan-Meier Curves and Survival Table for the End Point of TVR to 1,080 Days
In patients treated with the Cypher stent (Cordis), freedom from target vessel revascularization (TVR) remains significantly better than vascular brachytherapy throughout the 3-year follow-up period (log-rank p = 0.022).
|
|
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Kaplan-Meier Curves and Survival Table for the End Point of TVF to 1,080 Days
In patients treated with the Cypher stent (Cordis), the difference in freedom from target lesion revascularization from vascular brachytherapy is attenuated throughout the 3-year follow-up period (log-rank p = 0.087). TVF = target vessel failure.
|
|
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Kaplan-Meier Curves and Survival Table for the End Point of MACE to 1,080 Days
In patients treated with the Cypher stent (Cordis), the difference in major adverse cardiac events (MACE) from vascular brachytherapy is attenuated throughout the 3-year follow-up period (log-rank p = 0.186)
|
|
|
